SCHEMBL7961576

SCHEMBL7961576

CCc1c(CC(N)=O)c2cc(O)ccc2n1Cc1cccc(Cl)c1

nearest known ligand 0.82

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 20/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7961676 0.90 PLA2G2A (1.00) PLA2G2A
SCHEMBL7964724 0.87 PLA2G2A (0.81) PLA2G2A
SCHEMBL7962842 0.87 PLA2G2A (0.83) PLA2G2A
SCHEMBL7964798 0.82 PLA2G2A (0.77) PLA2G2A
SCHEMBL2002826 0.81 PLA2G2A (0.72) PLA2G2A
SCHEMBL2001954 0.81 PLA2G2A (0.83) PLA2G2A
SCHEMBL8926069 0.81 PLA2G2A (0.68) PLA2G2A
SCHEMBL7963980 0.80 PLA2G2A (1.00) PLA2G2A
SCHEMBL27379322 0.80 PLA2G2A (0.80) PLA2G2A
SCHEMBL8926065 0.80 PLA2G2A (0.64) PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1068588-C 1H-indole-3-acetamide splA2 inhibitors LILLY CO ELI (US) 2001-07-18 CN disclosed
US-6252084-B1 THERAPY FOR SEPSIS SHOCK ELI LILLY AND COMPANY 2001-06-26 US disclosed
EP-0620215-B1 1H-indole-3-acetamide derivatives as sPLA2 inhibitors LILLY CO ELI (US) 1999-08-18 EP disclosed
US-5684034-A INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE ELI LILLY AND COMPANY (US) 1997-11-04 US disclosed
CN-1098715-A PLA 2 inhibitors 1H-indole-3-acetamide compounds LILLY CO ELI (US) 1995-02-15 CN disclosed
EP-0620215-A1 1H-indole-3-acetamide derivatives as sPLA2 inhibitors ELI LILLY AND COMPANY (US) 1994-10-19 EP disclosed